secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0000950170-25-113371
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa requests FDA Type C meeting to accelerate low-dose (Z)-endoxifen for breast cancer risk reduction
--------------------------------------------------------------------------------

- Company requested a Type C FDA meeting; expects update by year-end 2025.
- Favorable outcome could shorten approval timeline by years and avoid tens of millions in trial costs.
- Cash position of $57.9M with no debt as of June 30, 2025; potential multi-billion-dollar market highlighted.
- Annual U.S. tamoxifen prescriptions estimated at 1.6-2.1 million; 4.3M women live with breast cancer history.
- (Z)-endoxifen avoids CYP2D6 metabolism issues affecting ~20% of tamoxifen patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025113371/0000950170-25-113371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025113371/atos-20250908.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-113371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer